Idioma:

Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma

Rizzieri, David A. ; Sand, Gregory J. ; McGaughey, Dean ; Moore, Joseph O. ; DeCastro, Carlos ; Chao, Nelson J. ; Vredenburgh, James J. ; Gasparetto, Cristina ; Long, Gwynn D. ; Anderson, Elizabeth ; Foster, Tracy ; Toaso, Bonnie ; Adams, Donna ; Niedzwiecki, Donna ; Gockerman, Jon P.

Cancer, 2004-06, Vol.100 (11), p.2408-2414 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por

Enviar para

Título:
Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma
Autor: Rizzieri, David A. ; Sand, Gregory J. ; McGaughey, Dean ; Moore, Joseph O. ; DeCastro, Carlos ; Chao, Nelson J. ; Vredenburgh, James J. ; Gasparetto, Cristina ; Long, Gwynn D. ; Anderson, Elizabeth ; Foster, Tracy ; Toaso, Bonnie ; Adams, Donna ; Niedzwiecki, Donna ; Gockerman, Jon P.
Assuntos: Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Phytogenic - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biological and medical sciences ; Carcinoma - drug therapy ; Carcinoma - pathology ; Female ; Hematologic and hematopoietic diseases ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma, Mantle-Cell - drug therapy ; Lymphoma, Mantle-Cell - pathology ; Lymphoma, Non-Hodgkin - drug therapy ; Lymphoma, Non-Hodgkin - pathology ; Male ; Maximum Tolerated Dose ; Medical sciences ; Microcirculation ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - pathology ; non‐Hodgkin lymphoma (NHL) ; paclitaxel ; Paclitaxel - administration & dosage ; recurrent ; refractory ; Remission Induction ; response ; Salvage Therapy
É parte de: Cancer, 2004-06, Vol.100 (11), p.2408-2414
Notas: Fax: (919) 668‐1091
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: BACKGROUND Many patients with recurrent, intermediate or high‐grade non‐Hodgkin lymphoma (NHL) may not respond to or are not candidates for aggressive salvage chemotherapy. Effective, less toxic regimens are needed. Although high‐dose taxanes have not been reported to be very effective for the treatment of lymphoma, different delivery rates may allow for different mechanisms of action to be manifest and result in a different toxicity profile and response rate. The current study tested this hypothesis by using low‐dose, weekly paclitaxel in patients with recurrent or refractory NHL. METHODS Adults age > 18 years with refractory or recurrent, aggressive NHL who were not considered curable with standard high‐dose therapy received paclitaxel at a dose of 80 mg/m2 weekly for 5 weeks for 2 cycles. RESULTS Thirty‐four patients with refractory NHL and 4 patients with recurrent disease were treated. Approximately 45% of the patients had achieved a prior disease remission. The median number of prior regimens received was 3, 74% of the patients had an International Prognostic Index of ≥ 3 at the time of study entry, and 29% had failed high‐dose therapy with autologous hematopoietic support. Only one patient encountered severe toxicity (sepsis). Myelosuppression was reported to occur in approximately 20% of patients. A total of 10 patients (26%) achieved a complete disease response and 4 patients (11%) achieved a partial response. CONCLUSIONS In the current study, low‐dose, weekly paclitaxel therapy was found to provide a well tolerated and less toxic approach to the treatment of refractory NHL, with encouraging responses noted in heavily pretreated patients. However, evaluation in patients with an earlier stage of disease is warranted. Cancer 2004. © 2004 American Cancer Society. Many patients with recurrent, intermediate or high‐grade non‐Hodgkin lymphoma (NHL) may not respond to or are not candidates for aggressive salvage chemotherapy. Therefore, effective, less toxic regimens are needed. Different delivery rates may allow for different mechanisms of action and result in a different toxicity profile and response rate for agents not felt to be effective with standard bolus regimens. The current prospective study tested this hypothesis by using low‐dose, weekly paclitaxel in patients with recurrent or refractory NHL
Editor: Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma

Rizzieri, David A. ; Sand, Gregory J. ; McGaughey, Dean ; Moore, Joseph O. ; DeCastro, Carlos ; Chao, Nelson J. ; Vredenburgh, James J. ; Gasparetto, Cristina ; Long, Gwynn D. ; Anderson, Elizabeth ; Foster, Tracy ; Toaso, Bonnie ; Adams, Donna ; Niedzwiecki, Donna ; Gockerman, Jon P.

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Buscando em bases de dados remotas. Favor aguardar.